Alyeska Investment Group L.P. purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 85,000 shares of the company's stock, valued at approximately $1,397,000. Alyeska Investment Group L.P. owned approximately 0.16% of Upstream Bio at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC purchased a new stake in Upstream Bio in the fourth quarter worth $117,977,000. Decheng Capital LLC bought a new position in shares of Upstream Bio in the fourth quarter worth $54,010,000. TCG Crossover Management LLC purchased a new position in Upstream Bio during the fourth quarter worth about $44,856,000. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Upstream Bio during the fourth quarter worth about $37,735,000. Finally, Samsara BioCapital LLC purchased a new position in Upstream Bio in the 4th quarter worth approximately $36,450,000.
Upstream Bio Stock Up 4.5%
Shares of NASDAQ UPB traded up $0.40 during trading hours on Monday, hitting $9.22. The company's stock had a trading volume of 36,525 shares, compared to its average volume of 326,213. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The business has a 50-day simple moving average of $8.03 and a 200-day simple moving average of $13.42.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Sell-side analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
